Sign in
Active, not recruitingPhase 2

A Study of SHJ002 Sterile Ophthalmic Solution for Myopia Control

Key facts

Who runs it
Sunhawk Vision Biotech, Inc.
Where
Hillsboro, United StatesSee the siteAlso in 1 other country, 8 sites
Trial code
Status
Active, not recruiting
Phase
Phase 2
People taking part
140 people enrolled
Started
22 Jan 2025
Expected to end
Dec 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • SHJ002
  • Atropine
Record updated
23 January 2026

Who can take part

Age
3 years to 12 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Be male or female, age 3-12 years (inclusive)
  • Cycloplegic sphere of -1.00 D or worse in both eyes
  • Able to complete all study assessments and comply with the protocol
  • Literate or able to orally communicate
  • Parent or guardian able and willing to provide written informed consent
  • Parent or guardian able and willing to assure subject compliance with the protocol, follow study instructions, and attend study visits
  • Able to tolerate eye drops in both eyes
  • Be able and willing to avoid all disallowed medications and refractive correction
  • For female subjects of childbearing potential (those who have experienced menarche and who are not surgically sterilized [bilateral tubal ligation, hysterectomy, or bilateral oophorectomy]), a negative urinary test
  • Women of childbearing potential must agree to use two reliable methods of contraception
  • Males not naturally or surgically sterile, who have a female partner of childbearing potential, must agree to use two reliable methods of contraception

Who cannot take part

  • Previous incisional or laser surgery
  • Active or recent history of severe ocular infection or inflammation
  • Axial length > 26 mm
  • Anisometropia
  • Astigmatism > 2.00 D
  • Intraocular pressure > 21 mm Hg or < 6 mm Hg
  • Any clinically significant finding on slit lamp biomicroscopy or ophthalmoscopy

Where in United States

Also in 1 other country, 8 sites

  • Pacific Center for Advanced Vision Care Tanasbourne Vision CenterHillsboro, United States

About the trial

What the trial wants to find out

The objective of this study is to explore the safety and efficacy of SHJ002 Sterile Ophthalmic Solution relative to atropine in myopia control

Read full original descriptionShow less

SHJ002 is an antisense oligonucleotide to neutralize a specific microRNA.

The 2 groups in the trial

  • SHJ002Treatment being tested

    The assigned eyedrops will be instilled in both eyes once per day, one drop per application, 7 days a week, for 52 weeks.

  • AtropineExisting treatment, for comparison

    The assigned eyedrops will be instilled in both eyes once per day, one drop per application, 7 days a week, for 52 weeks.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase II Study to Determine the Safety and Efficacy of SHJ002 Sterile Ophthalmic Solution on Myopia Control in Subjects Aged 3-12 Years.
Record updated
23 January 2026